Nutlin-Based MDM2 Degrader for Osteogenic Stem Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate in effectively inducing osteogenic differentiation of stem cells, which is crucial for bone tissue regeneration and repair.
Innovation Solution
A novel compound, stereoisomer, or pharmaceutically acceptable salt thereof, specifically targeting MDM2 via an E3 ligand, is developed to induce osteogenic differentiation of stem cells by utilizing the ubiquitin-proteasome system (UPS) for targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to induce osteogenic differentiation of stem cells, then the process is simpler, but the effectiveness and efficiency of bone tissue regeneration is insufficient
Solution Approach 1:
The compound is divided into three functional segments: an E3 ligand module that binds to E3 ubiquitin ligase, an MDM2 ligand module that binds to the target protein MDM2, and a linker that connects them. This segmentation allows each module to perform its specific function independently while working together to achieve the overall goal of inducing osteogenic differentiation through targeted protein degradation.
Solution Approach 2:
The compound acts as an intermediary molecule that bridges the E3 ubiquitin ligase and MDM2 target protein. By containing both binding modules, it mediates the interaction between these two proteins, enabling the E3 ligase to ubiquitinate and degrade MDM2, thereby inducing osteogenic differentiation through the ubiquitin-proteasome system.
2Productivity
If the ubiquitin-proteasome system is utilized for targeted protein degradation, then osteogenic differentiation is effectively induced, but the mechanism becomes more complex
Solution Approach 1:
The compound is designed with pre-assembled E3 ligand and MDM2 ligand modules connected by a linker, creating a ready-to-use ternary complex formation system. When the compound binds to both E3 ligase and MDM2 simultaneously, it preliminarily positions them in close proximity, facilitating rapid ubiquitination and degradation of MDM2, thereby accelerating osteogenic differentiation.
Solution Approach 2:
The compound represents a composite molecular structure combining heterocyclic compounds (E3 ligand) and coumarin derivatives (MDM2 ligand) connected through a linker. This composite design integrates the binding specificities of different molecular classes into a single agent that can simultaneously engage multiple protein targets through the ubiquitin-proteasome system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively promotes osteogenic differentiation of stem cells, enhancing bone tissue regeneration and repair by activating key signaling pathways.
Implementation Method 1
when small molecules that specifically recognize target proteins and small molecules that specifically recognize E3 recognize E3 and binds to the E3, the E3 and the target protein become close to each other, inducing E3-mediated polyubiquitination of the target protein
Implementation Method 2
Induction of polyubiquitination within the cell ultimately leads to the recognition of the polypolyubiquitinized target protein by the 26S proteasome, an ATP-dependent protease complex, causing degradation via the unregulated protein transporter (UPS)
Data Source
Figure 1a~1b
Figure 2~3b
Figure 3c
AI summary
The present invention relates to a novel compound capable of inducing osteogenic differentiation of stem cells and, more particularly, to a compound of chemical formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a composition for inducing osteogenic differentiation of stem cells, comprising the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof. The novel compound based on nutlin, according to the present invention, induces the degradation of MDM2 to efficiently promote the differentiation of mesenchymal stromal cells, and thus, the effect of inducing osteogenic differentiation of stem cells is excellent.